ea0099rc12.1 | Rapid Communications 12: Diabetes, Obesity, Metabolism and Nutrition | Part II | ECE2024
Geiger Niklas
, Kloock Simon
, Gerner Jana
, Landthaler Aisha-Nike
, Nickel Alexander
, Kohlhaas Michael
, Geier Andreas
, Fassnacht Martin
, Dischinger Ulrich
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common comorbidity of obesity. In this study, we sought to determine hepatic metabolic and mitochondrial effects of the Glucagon-like Peptide-1-agonist semaglutide, the sodium-glucose linked transporter 2-inhibitor empagliflozin and Peptide YY3-36 in diet-induced obese rats with additional chronic inhibition of nitric oxide synthase via Nω-nitro-L-arginine meth...